MarketPulse

Chinese biotech

2 articles
BenzingaBenzinga··Bamboo Works

Keymed's $320M Windfall: Chinese Biotech Scores Major Exit via Gilead Acquisition

Keymed Biosciences receives up to $320M from Gilead's acquisition of its immunotherapy spinoff Ouro Medicines, marking a landmark exit for Chinese biotech.
AZNGILDacquisitionautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Royalty Pharma Bets Big on Asia Boom With New Regional Leadership

Royalty Pharma appoints Morgan Stanley veteran Kenneth Sun as SVP to lead Asia expansion, targeting region's surging biotech market and $130B medicine licensing opportunity.
MSMSpAMSpEMSpFMSpI+6Asia expansionnon-dilutive capital